Prescribing of proton pump inhibitors for gastrointestinal bleeding prophylaxis in the Lebanese outpatient setting: patterns, compliance with guidelines and risks

• Published in: The International journal of pharmacy practice 2019-08, Vol.27 (4), p.386-392
• Main Authors: Soubra, Lama, Issa, Mohamed
• Format: Article
• Language: English
• Subjects: Adult; Ambulatory Care - standards; Ambulatory Care - statistics & numerical data; Anti-Inflammatory Agents, Non-Steroidal - adverse effects; Antidepressants; Bisphosphonates; community setting; Compliance; Cross-Sectional Studies; Drug Prescriptions - standards; Drug Prescriptions - statistics & numerical data; Female; gastrointestinal bleeding prophylaxis; gastrointestinal bleeding risk assessment; Gastrointestinal Hemorrhage - chemically induced; Gastrointestinal Hemorrhage - prevention & control; Guideline Adherence - statistics & numerical data; Humans; Inappropriate Prescribing - prevention & control; Inappropriate Prescribing - statistics & numerical data; Lebanon; Male; Middle Aged; Practice Guidelines as Topic; Practice Patterns, Physicians' - standards; Practice Patterns, Physicians' - statistics & numerical data; Prospective Studies; proton pump inhibitor (s); Proton Pump Inhibitors - therapeutic use; Surveys and Questionnaires - statistics & numerical data; Young Adult
• ISSN: 0961-7671; 2042-7174
• DOI: 10.1111/ijpp.12537

Objectives To determine patterns of proton pump inhibitor (PPIs) prescribing for gastrointestinal bleeding prophylaxis (GIBP) in the Lebanese outpatient setting, to assess their compliance with guidelines for approved GIBP indications and to delineate independent factors that are associated with non‐compliance. Methods A community‐based multicentre cross‐sectional study was conducted. Eligible patients were those who presented to the community pharmacy setting with a PPI prescription for GIBP. Prescriptions were reviewed by a clinical pharmacist to ascertain their compliance with guidelines approved for GIBP indications. Several variables were tested to determine independent factors that were associated with guidelines non‐compliance. Key findings Of the 720 reviewed PPI prescriptions, 297 (41.25%) were found to be compliant with guidelines approved for GIBP indications. The presence of two or more comorbid conditions, prescribing initiated by a primary care physician, patients taking three or more medications, and prescribing of NSAIDs including low‐dose aspirin were found to be independent factors that were significantly associated with PPI prescribing non‐compliance (P ≤ 0.05). PPIs were also inappropriately coprescribed with corticosteroids (102 (24.1%)), selective serotonin reuptake inhibitors (SSRIs) (48 (11.4%)), amoxicillin‐clavulanic acid (20 (4.7%)) and bisphosphonates (13 (3.1%)) for GIBP. Conclusion This study demonstrated that PPIs were appropriately prescribed for GIBP in less than the half of the study patients. The need for improvement of clinical practice in this regard is therefore indispensable since inappropriate prescribing is costly and put the patient at risk for adverse health outcomes. Strategies to alter inappropriate prescribing may include education, guidelines awareness and decision support systems.